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Abstract
Background High-throughput proteomics techniques, such as mass spectrometry (MS)-based
approaches, produce very high-dimensional data-sets. In a clinical setting one is often interested in
how mass spectra differ between patients of different classes, for example spectra from healthy
patients vs. spectra from patients having a particular disease. Machine learning algorithms are needed
to (a) identify these discriminating features and (b) classify unknown spectra based on this feature set.
Since the acquired data is usually noisy, the algorithms should be robust against noise and outliers,
while the identified feature set should be as small as possible.
Results We present a new algorithm, Sparse Proteomics Analysis (SPA), based on the theory of
compressed sensing that allows us to identify a minimal discriminating set of features from mass
spectrometry data-sets. We show (1) how our method performs on artificial and real-world data-sets,
(2) that its performance is competitive with standard (and widely used) algorithms for analyzing
proteomics data, and (3) that it is robust against random and systematic noise. We further
demonstrate the applicability of our algorithm to two previously published clinical data-sets.
Availability of data and methods
The method source-code can be downloaded from our homepage:
http://software.medicalbioinformatics.de. The used data will be made available through
BioMed Central.
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1 Introduction
During the last decade, high-throughput assays systems1 for measuring a variety of different biological
sources have become standard in modern laboratories. This allows for the quick and cheap creation of
very large data-sets which characterize for example the status of a cell by its billions of constituents,
e.g. nucleotides, RNAs, contained proteins, or metabolites. Ideally, analyzing these massive data-sets
leads to a better understanding of the underlying biological processes. Especially in the context of
characterizing—and ultimately understanding—diseases, a first step is often to find significant
differences in the data between samples from healthy and diseased individuals. There are many
successful examples where this approach based on -omics data (e.g., genomics, proteomics, or
metabolomics) led to the identification of biological markers, enabling a new type of molecular
diagnostics. We call a collection of biological markers that represents the differences on the data level
a disease fingerprint.
Many disease-relevant mechanisms are controlled by proteins (e.g. hormones), which can be
detected in biological samples (blood, urine, etc.) using mass spectrometry (MS ). This technique
allows (potentially) for monitoring the entire set of proteins—the so-called proteome—in a given
sample. Due to its wide availability in hospitals, MS-based proteomics can bring the next wave of
progress in diagnostics, since even subtle changes in the proteome can be detected and linked to
disease onset and progression [2–5].
Disease Fingerprints: The main idea of the identification of disease fingerprints using
MS-based proteomics is sketched in Fig. 1:
(a) A mass spectrum is generated reflecting the constitution of a given (blood-)sample with respect
to contained molecules. (b) Based on mass spectra from two sample groups (representing a healthy
control group and a group having a particular disease) differences are detected. This set of differences
precisely corresponds to a disease fingerprint, since it represents a trace caused by a particular disease
in the proteome. Several studies have shown that this approach works well in practice and found
differences do indeed reflect correlations between changes in the mass spectrum, the proteome, and
phenotypic changes ( [6–10]). Panels of proteomic markers (fingerprints) have been shown to be more
sensitive and specific than conventionally biomarker approaches [3], for example when diagnosing
cancer [11–13]. However, a single proteomics data-set can contain tens of millions of signals which is
many orders of magnitudes larger than the number of available observations in a typical study.
Our ultimate goal is therefore to build a library of proteomics disease fingerprints which are
extracted from high-throughput MS experiments. These would enable to diagnose diseases based on
their proteomic fingerprints—just by analyzing an individual’s proteome. Ideally, these fingerprints
are of low-complexity allowing easy interpretation by experts, e.g. medical doctors, and the
implementation of medical assays for routine diagnostics, e.g. in an hospital environment. Clearly, the
less components an assay is composed of, the easier it is to implement and interpret.
Thus, a fingerprint should only consist of a minimal collection of proteins specific for a particular
disease and should be robust against noisy measurements. On the other hand, the acquired data from
the high-throughput experiments is very high-dimensional and contains large amounts of random and
systematic noise which makes an automatic analysis of mass spectra a very challenging task. Hence,
the discovery of biomarkers is still a widely open research topic and there are several analytic
problems that hinder reproduction of results (see [14] for example).
Despite these challenges there is indeed hope that these disease specific, low-complexity fingerprints
exist: It has been shown for several cancer types that a small numbers of genes and proteins can be
identified that serve as biomarkers (e.g. for lung cancer [15], breast cancer [16] or pancreas cancer [17]).
This means that only a few signals in a mass spectrum can be used to derive a sparse classifier.
MS1 Data: In this work we consider mass spectrometry (MS) data acquired from a standard
MALDI-TOF instrument because it is easy to obtain using comparatively cheap MS-instruments
1 Assays, e.g. immunoassays, are used in molecular diagnostics to detect concentrations of specific molecules even in low
concentrations from a biological sample, such as blood [1].
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Figure 1. (a) Schematic outline of a linear matrix-assisted laser desorption ionization (MALDI)–time-of-flight
(TOF) mass spectrometer (MS). During the measurement process, the molecules of the examined sample are
ionized, vaporized and finally analyzed by their respective time-of-flight through an electric field. This process
generates a plot (mass spectrum) having mass-to-charge ratio (m/z) on the x-axis and intensity (ion count) on
the y-axis. (b) Typical mass spectrum for a mass range of 1500–10.000 Dalton. (c) Example of a disease
fingerprint, created by comparing mass spectra from a healthy and a diseased individual.
which are widely available, e.g. in hospitals. Opposed to other approaches such as tandem mass
spectrometry (MS/MS), we directly work on the raw data acquired in profile mode and do not aim for
identification. Thus, each mass spectrum (sample) always has the same number of d dimensions
(number of entries). 2 Recall, that the entries in a mass spectrum are a weight-ordered list of
ion-counts of the respective ion-masses. (See also Fig. 1.)
One of the reasons for this is that standard approaches for MS data analysis usually convert the
MS data to peak lists as a first step and work on the converted data. However, signals can be missed
by this conversion step due to noise or missing values in the raw data which hinders peak detection.
Opposed to this, our approach does not rely on any peak identification but works on the raw data.
This allows for a more robust analysis in presence of noise which is a typical challenge in MS data
analysis.
1.1 Problem Definition
In this article, we will focus on the following problem setting:
We assume that we are given data of n mass spectra derived from n biological samples (e.g. from
blood of n individual patients) in form of n pairs {(xi, yi)}i=1...n. Here, xi ∈ Rd represents the mass
spectrum of the i-th sample (e.g. the i-th patient) and yi ∈ {−1,+1} its respective class, e.g., healthy
or diseased. Thus, each xi (representing an individual mass spectrum) contains d entries. The goal is
to identify a (small) set of features, i.e. indices in the mass spectrum, separating these two classes.
Thus, a feature represents a specific position (or mass) in a mass spectrum in which the two groups
(e.g. healthy vs. diseased) differ. This corresponds to the well known problem of feature selection3 and
leads to a potential disease fingerprint for the given data.
Mathematically, this can be formulated as the identification of a feature vector
ω0 = (ω0,1, . . . , ω0,d) ∈ Rd such that4
yi = sign(fω0(xi)) for “many” samples i = 1, . . . , n, (1)
with a linear decision function fω0(xi) := 〈ω0, xi〉 =
∑d
j=1 ω0,jxi,j .
2 The data-sets used in this paper contain d = 42.381 dimensions in each MS1 spectrum but our approach is not limited
by that. 3 In feature selection, one is interested in identifying relevant dimensions of the data (features) which can be
used to distinguish between two (or more) classes within a data-set. 4 Here, sign(·) denotes the sign function, i.e.,
sign(t) = 1 if t ≥ 0 and sign(t) = −1 if t < 0.
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From a geometric perspective, this means that the hyperplane with normal vector ω0 appropriately
separates the data-points of the respective classes. This means that ω0 can be used as a linear classifier
where each entry of ω0 corresponds to a specific position in a spectrum and the non-zero entries (which
we call features) indicate their significance. Our goal is therefore to learn a sparse ω0 for which Eqn. 1
holds. As a particular consequence, a classifier based on such ω0 will yield good prediction accuracy.
In most realistic scenarios for feature selection, unfortunately, the number of features is much
larger than available samples (d n) and the data suffers from noisy measurements. For these
reasons, the number of feasible classifiers ω0 can become extremely large, so that the problem of
overfitting can occur. In order to allow interpretability and generalization of the classifier, it is in fact
inevitable to restrict the solution space for ω0. In this paper, we focus on very sparse
5 vectors ω0
satisfying (1), which precisely reflects our wish for a minimal disease fingerprint.
At this point, it should be emphasized that (1) does not need to hold for all samples but rather for
most of them. Allowing for such a small “mismatch” in the model, we incorporate the crucial fact that
a simple binary output model, such as (1), might describe the disease label only with high accuracy
but not necessarily exactly. In turn, this asks for a certain robustness of the used method against
wrong predictions with regard to (1).
We will approach this challenge by formulating the feature selection problem as a constrained (or
regularized) optimization problem:
min
ω∈Rd
n∑
i=1
L(yi, fω(xi)) subject to R(ω) ≤ λ, (2)
where L : R× R→ R is a loss (error) function, R : R→ R is a regularization (cost) function that
encourages a particular structure of ω (e.g., sparsity), and the parameter λ ≥ 0 controls the degree of
model complexity. Given any potential feature vector ω and the (true) output label y, the loss
function L(y, fω(x)) measures the discrepancy between the actual and the desired prediction.
As already pointed out, we are particularly interested in a method that produces optimal and robust
solutions in the following situation:
• The input data (x, y) are noisy,
• the number of data dimensions d is large (typically: d = 105 . . . 108),
• the number of samples n is relatively small (typically: n = 102 . . . 104), and
• the set of highly-relevant features is small (i.e., a minimal disease fingerprint indeed exists),
which corresponds to a small number of non-zero elements in ω0 (typically:
#{i | ω0,i 6= 0}  100).
On the contrary, we are not mainly interested in the methods’ overall classification performance.
Measures of classification performance such as accuracy are indicators whether a learned classifier
accurately separates the data into classes. In our case, we assume that the data can be characterized
well by a sparse classifier ω0 whose non-zero entries are those used for classification and are therefore
of medical relevance. That means, if ω0 is sparse and leads to good classification accuracy then only a
few entries contribute and medical interpretation becomes feasible. However, if there does not exists a
sparse ω0 such that Eqn. 1 holds, there is strong evidence that no sparse (simple) characterization is
possible. This indicates that the underlying biological mechanisms are too complex to be captured by
a sparse (simple) model. If this is the case, every sparsity-encouraging method will fail, meaning that
a sparse classifier will always give poor classification. As a consequence, an important assumption of
this work is that a sparse ω0 (ground-truth) exists.
5 We call a vector sparse if the number of non-zero entries is small.
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Name Loss function (L) Regularizer (R)
AIC/BIC ‖y − 〈ω, x〉‖2 ‖ω‖0
Lasso ‖y − 〈ω, x〉‖2 ‖ω‖1
Elastic Net ‖y − 〈ω, x〉‖2 ‖ω‖22 + ‖ω‖1
Regularized Least Absolute
Deviations Regression ‖y − 〈ω, x〉‖1 ‖ω‖1
Classic SVM max(0, 1− y〈ω, x〉)* 12‖ω‖22
`1-SVM max(0, 1− y〈ω, x〉)* 12‖ω‖1
Logistic Regression log(1 + exp(−y〈ω, x〉)) 12‖ω‖1
*This is the so called Hinge loss.
Table 1. Prominent options for choosing loss function and regularizer in feature extraction algorithms. The
`1- and `2-norm of a vector z = (z1, . . . , zd) ∈ Rd are defined by ‖z‖1 =
∑d
j=1 |zi| and ‖z‖2 = (
∑d
j=1 |zi|2)1/2,
respectively. The “`0-norm” ‖z‖0, simply counts the number of non-zero entries of z.
As we will see later it is often possible to find non-sparse classifiers which achieve better
classification accuracy. This might be favorable in some situations in which the main focus is indeed
on overall classification accuracy. However, in these situations overfitting becomes an issue and the
identification of interpretable, highly-discriminative features might be extremely difficult. In the
context of MS-data analysis such a classifier would be especially hard to interpret because of the very
high dimensionality of the data.
1.2 State of the Art in Sparse Feature Selection
There are numerous approaches for feature selection which mainly fall into three categories:
• Filters: Using some score or correlation function (e.g., based on Fisher’s, t-test, information
theoretic criteria) evaluating the importance of each feature in a univariate way and taking the
top-rated features.
• Wrappers: Using machine-learning algorithms to evaluate and choose features using some
search strategy (e.g. simulated annealing or genetic algorithms).
• Embedded methods: Selecting variables by directly optimizing an objective function (usually
in a multivariate way) with respect to: goodness-of-fit and (optionally) number of features. This
could be achieved with algorithms like least-square regression, support vector machines (SVM),
or decision trees.
In this paper, we will mainly focus on embedded methods. Regarding this category, the literature
contains several well-known options for choosing combinations of loss and regularization functions (cf.
(2)), some of which are exemplarily listed in Table 1.
Different combinations can influence the results dramatically: Fig. 2 demonstrates the effect of
sparsity by comparing a `2- and `1-regularized version. In this example, a proteomics data-set was
created that contains three discriminant features between the two sub-groups. It can be easily seen
how the results differ: While the `1-based result is optimized for selecting only a few features, the
`2-variant selects much more features which in turn results in a better fit of the observation model. In
this paper, we are interested in developing a method that selects as few features as possible while
achieving the best possible fit under this constraint. This is in contrast to methods that aim at only
achieving the best possible fit. A low-complexity model is of particular interest in biological
applications because each selected feature is usually analyzed in subsequent experiments, which
creates additional costs.
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Figure 2. (a) Overlaid spectra from two different groups. The three peaks marked by the arrows (magnified
in the inlays) represent the underlying differences between the two groups. (b) Sparse ω found by a
`1-regularized method (`1-SVM). (c) ω found by `2-regularized method (classical SVM).
Various approaches can be used to assess the outcome ω of a feature selection method, when
appropriate training and test data are available. We will use the following three measures of quality:
(i) correctness of the selected features, (ii) size of the selected feature set, (iii) performance of
classifying an unknown test set (specificity, sensitivity, accuracy). Obviously, (i) can only be used if
the correct features are known, which is the case in our benchmark data-sets (for more details see
Section 4).
1.3 Contribution
As already mentioned above, the major challenge of sparse feature extraction is to robustly identify a
small set of variables (non-zero components of ω) that can be used to accurately classify unknown
proteomics data (e.g. healthy or diseased) according to (1). This paper introduces Sparse Proteomics
Analysis (SPA), a novel framework for feature selection and classification. The key step of our method
is based on 1-bit compressed sensing (cf. Section 2) and solves the following optimization problem:6
max
ω∈Rd
n∑
i=1
yi〈xi, ω〉 subject to ‖ω‖1 ≤
√
λ and ‖ω‖2 ≤ 1, (3)
where the regularization is now defined by two inequality constraints on the feature vector ω.7 The
above approach is motivated by the general theory of compressed sensing, which was originally
introduced by Donoho as well as by Cande`s, Romberg, and Tao (cf. [18–20]) and provides a modern
framework for efficiently acquiring and processing high-dimensional (nearly) sparse signals (for more
details see Section 2).
We shall verify the competitiveness of our method by applying it to several synthetic and
real-world data-sets and comparing the results to those of other widely-used algorithms in this field.
Although the core of the algorithm (3) is surprisingly simple, we will observe that SPA (including pre-
and postprocessing steps) finds optimal feature vectors which are extremely sparse, allow for highly
accurate classification, and are robust against noise. In particular, for “very-sparse” situations, it even
turns out that SPA outperforms the standard methods listed in Table 1.
Note that computational solutions to (2) or (3) are usually based on solving a convex program by
standard optimization techniques, such as interior point methods. However, these methods sometimes
scale poorly with increasing number of samples n and data dimension d, as it is typically the case for
6 Here, 〈·, ·〉 again denotes the Euclidean scalar product. 7 For the sake of convenience, we formulate our algorithm as
in (3), but with some slight modifications, it could be equivalently stated in the form of (2).
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-omics data analysis. Several strategies have been proposed in the literature to speed up the
calculations, e.g., using stochastic decent ( [21–25]). In this article, we shall not focus on such
computational issues but rather on providing a novel way of formalizing and solving the feature
selection problem, namely in the context of compressed sensing.
Apart from the specific approach of (3), it is a general concern of this work to promote the benefit
of sparse embedded methods. In contrast to classical (univariate) approaches, such as statistical tests,
the process of variable selection takes place in an automatic fashion here. In this way, a costly
preprocessing (e.g., peak detection) as well as subsequent feature assessments can be avoided as much
as possible. Especially in a situation where only a very few samples are available, those additional
steps may cause further instability and their success strongly relies on the specific data structure. In
fact, it was already succinctly emphasized by Vapnik in [26, p. 12] that
“If you possess a restricted amount of information for solving some problem, try to solve the problem
directly and never solve the more general problem as an intermediate step. It is possible that the
available information is sufficient for a direct solution but is insufficient for solving a more general
intermediate problem.”
This fundamental principle is precisely reflected by our viewpoint, which only makes a few (generic)
assumptions on the underlying data model. Finally, we would like to mention that recently, rigorous
theoretical guarantees for sparse feature selection from MS data were shown in [27]. Using the novel
idea of optimal problem representations, the mathematical framework of [27] even goes beyond the
binary output scheme of (1) and allows for a unified treatment of general observation and data models.
1.4 Outline of this Paper
We start by shortly reviewing the background of compressed sensing in Section 2, and then describe
our novel feature selection approach SPA in detail (Section 3). Finally, we present several benchmark
results in Sections 4 and 5 for simulated and real data-sets and compare them to current
state-of-the-art algorithms.
2 Background: Compressed Sensing
2.1 Compressed Sensing-Based Data Analysis
In its most simple form, compressed sensing (CS ) studies the recovery of an unknown vector x ∈ Rd
from linear measurements y = Ax. Here, A ∈ Rn×d is an (n× d)-matrix and the entries of y ∈ Rn
contain the measurements. The major challenge is now to design the measurement process A in such a
way that the number of measurements n is as small as possible and, at the same time, x is still
(uniquely) recoverable from y. Thus, we are asking for the maximal compressibility of x by linear
measurements.
Obviously, when n d, we require some additional information to obtain a unique solution of
y = Ax. The prior information on x which is studied in compressed sensing is the assumption of
sparsity, i.e., most coefficients of x are assumed to be zero, or at least very small. One naive approach
to incorporate this additional property is to search for the sparsest solution of Az = y:8
argmin
z∈Rd
‖z‖0 subject to Az = y. (4)
Unfortunately, this problem is non-convex and cannot be efficiently solved in general. Therefore, one
usually replaces (4) by its convex relaxation, which is also known as the basis pursuit ( [28]):
argmin
z∈Rd
‖z‖1 subject to Az = y. (5)
8 Here, ‖z‖0 := #{i | zi 6= 0} simply counts the number of non-zero elements of z = (z1, . . . , zd) ∈ Rd.
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One of the first key results in compressed sensing states that, if A ∈ Rn×d is chosen randomly, e.g.,
with independent and identically distributed Gaussian entries, and n = O(s · log(d/s)), then (with
“high probability”) every s-sparse vector x (i.e., ‖x‖0 ≤ s) can be uniquely recovered from (5). The
most surprising fact is that the number of required measurements n = O(s · log(d/s)) only
logarithmically depends on the (possibly large) dimension d of the ambient space. Hence, random
measurement processes indeed allow for a very strong compression of sparse vectors (see also [18–20]
for more details).
In order to consider more complicated situations, the stability and robustness of the basis pursuit
algorithm was extensively studied. Various theoretical results and numerical experiments show that
this algorithmic approach can also be applied for the stable recovery of vectors which are only nearly
sparse, as well as to noisy measurements of the form y = Ax+ η. To obtain a robust version of (5),
one may replace its equality constraint by ‖Az − y‖2 ≤  for some appropriate noise level  > 0. Not
very surprisingly, this approach is also closely related to the Lasso introduced by Tibshirani in [29]
(see also (2) and Table 1).
2.2 1-Bit Compressed Sensing
In many practical scenarios, especially when working with computers, there is no way to represent real
numbers exactly. Thus, it is reasonable to assume that the measurement vector Ax is acquired in a
quantized (and therefore non-linear) fashion. The most extreme form directly leads to 1-bit
measurements, i.e., only the signs of Ax are known:
yi = sign(〈ai, x〉), i = 1, . . . , n, (6)
where a1, . . . , an ∈ Rd are the rows of the measurement matrix A ∈ Rn×d. As in classical compressed
sensing, we are asking for an appropriate recovery of x from (6) using as few measurements as possible.
This challenge was originally considered in [30] as 1-bit compressed sensing, and has been extensively
studied in [31,32].
A surprisingly simple convex recovery approach was proposed by Plan and Vershynin in [32]:
max
z∈Rd
n∑
i=1
yi〈ai, z〉 subject to ‖z‖1 ≤
√
λ and ‖z‖2 ≤ 1, (7)
where λ > 0 denotes the sparsity-controlling parameter. To get some intuition, we first note that we
have yi = sign(〈ai, x〉) if and only if yi〈ai, x〉 > 0 holds. Hence, maximizing the sum in (7) will ensure
the consistency of many measurements i ∈ {1, . . . , n}, according to (6). However, the total consistency
is not enforced so that (7) indeed allows for noisy inputs y that do not satisfy (6). On the other hand,
the constraint of (7) promotes sparsity of the final outcome. To see this, we may consider the set
Sd,λ := {z ∈ Rd : ‖z‖0 ≤ λ, ‖z‖2 ≤ 1} and observe that (cf. [32, Sec. III])9
conv(Sd,λ) ⊂ {z ∈ Rd : ‖z‖1 ≤
√
λ, ‖z‖2 ≤ 1} ⊂ 2 conv(Sd,λ).
This means that (7) optimizes over a convex relaxation of the set Sd,λ which contains all λ-sparse
vectors in the unit ball. For more details, see also [32]. The main statement of [32] proves that the
robust 1-bit compressed sensing algorithm (7) indeed allows for an appropriate recovery of sparse
vectors, using only n = O(λ · log(d/λ)) measurements. Moreover, it is surprisingly robust against
several types of noise, including (random) bit-flips of the labels.
Remark. The minimized functional of (7) is closely related to the hinge loss which is used for SVMs
(cf. Table 1). Indeed, without rejecting the negative part of the hinge loss, we would precisely end up
with the objective functional in (7).
The constraint of (7), on the other hand, can be regarded as a combined `1-`2-condition, where the
tuning parameter λ controls the desired level of sparsity of the minimizer. This type of regularization
strongly resembles the idea of elastic nets, originally proposed by Zou and Hastie in [33].
9 Here, conv(S) denotes the convex hull of the set S ⊂ Rd.
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2.3 Why Compressed Sensing?
At a first sight, the main challenges of compressed sensing and machine learning (ML) seem to be very
different. In compressed sensing, we intend to design a measurement process A in order to compress a
vector x, whereas in machine learning, the training data is already contained in the rows of A and we
are rather willing to explain the observations y by some appropriate vector x. However, in both areas
we are asking for a (sparse) recovery from a certain type of measurement. Indeed, a linear regression
in ML exactly corresponds to classical CS model (see Subsection 2.1), and a classification problem is
actually equivalent to 1-bit CS (see Subsection 2.2).
Therefore, it is not very surprising that the applied algorithms for compressed sensing and machine
learning resemble each other, and that theoretical results in both fields rely on the same mathematical
foundations (concentration of measure, convex geometry, etc.). Unfortunately, both communities only
rarely interacted with each other. In this paper, we would like to emphasize the viewpoint of
compressed sensing, in particular, because it is still not very common for the classification tasks that
we deal with.
With the recent progress in compressed sensing and related areas as low-rank matrix recovery or
quantized CS, also new algorithms like nuclear norm minimization or 1-bit CS have been proposed.
Although these methods are typically motivated by theoretical studies, they perform also very well for
real-world data. In general, we believe that these alternative perspectives allow for deeper theoretical
insights, finally leading to the improvement of the classical (`1-based) tools from machine learning.
For an extensive introduction to compressed sensing, we refer to [34, 35]. As we already mentioned
above, comparing this text to literature from statistical learning theory (see [36] for example), the
reader will quickly notice many interesting connections between both fields.
3 Sparse Proteomics Analysis (SPA)
In this section, we present the details of our novel framework which is based on the ideas of 1-bit
compressed sensing presented in the previous section. The first part provides a mathematical
formulation of the feature selection problem as well as a brief overview of the steps that are performed
in SPA. The rest of this section is then devoted to a detailed description and discussion of the single
steps.
3.1 Setting and Overview
As already mentioned in the introduction, we assume that our learning process is supervised, i.e., we
know which spectrum belongs to the class of healthy (yi = +1) and diseased (yi = −1) samples in
advance. If the data vectors xi ∈ Rd, i = 1, . . . , n are mass spectra, the indices j = 1, . . . , d of
xi = (xi,1, . . . , xi,d) correspond to the m/z-values
10 and its entries represent the intensities. The
non-zero entries of the feature vector ω0 = (ω0,1, . . . , ω0,d) ∈ Rd describe the location of the disease
fingerprints and its respective values the significance of these features.
In the setting of classical learning theory, we are asking for a hyperplane {ω0}⊥ which correctly
separates most of the data points xi labeled by yi. More precisely, this means
11
yi = sign(〈xi, ω0〉) for “many” samples i = 1, . . . , n. (8)
Equivalently, we can view (8) as a problem from 1-bit compressed sensing (cf. Section 2.3), i.e., we
have acquired noisy 1-bit measurements and are now looking for a sparse recovery.
In the development of SPA, we have primarily focused on the latter perspective, and therefore, the
1-bit recovery program (7) forms the key step of our algorithm:
10 m/z is the unit for the mass-to-charge ratio. 11 Compared to Section 2, we are now using the standard notations
from learning theory. In particular, the measurement vectors are denoted by xi (instead of ai) and the feature vector is
ω0 (instead of x).
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Algorithm 1 (SPA at a Glance).
Input: Raw data samples {(xi, yi)}i=1,...,n
Output: Sparse feature vector ω˜ ∈ Rd
Preprocessing:
1: Normalize data to make the spectra comparable.
2: Perform smoothing by a convolution with Gaussian density.
3: Standardize data.
Sparse Feature Selection:
4: Perform 1-bit CS optimization (7) to find feature vector ωˆ.
Postprocessing:
5: Detect the connected components of ωˆ to obtain a sparsified version ω˜.
6: (Optional) Reduce dimension by projecting data onto the feature space.
3.2 Algorithmic Details
In the following, we are going to specify and discuss the single steps of Algorithm 1.
Step 1: Normalization of the Data
This step heavily depends on the underlying acquisition method of the data. Every spectrum xi ∈ Rd
is normalized by a certain scaling factor µi > 0, i.e., xi 7→ µixi for i = 1, . . . , n. The individual scalars
µi should be chosen such that the resulting data vectors are “comparable.”
For example, when we assume that the data are acquired by MALDI-TOF-MS as described in
Fig. 1, it seems to be quite natural to normalize them by the total ion count. Mathematically, this
means that we would divide every spectrum by its `1-norm, i.e., we choose µi = 1/‖xi‖1.
Step 2: Smoothing by Gaussian Density
We already pointed out that one major challenge is the strong noise within the raw data. Therefore, it
is crucial to perform some noise reduction before trying to extract features. For this purpose, we
suggest a simple smoothing strategy by a Gaussian density:
Let Gσ denote the (centered) Gaussian density function with fixed standard deviation σ > 0, that
is,
Gσ(t) =
1√
2piσ2
exp
(
− t
2
2σ2
)
, t ∈ R.
The smoothed spectra x˜i = (x˜i,1, . . . , x˜i,d) ∈ Rd are then obtained by a discrete convolution
x˜i,k := (xi ∗Gσ)k =
d∑
l=1
xi,l ·Gσ(k − l), k = 1, . . . , d, i = 1, . . . , n. (9)
Using the fast Fourier transform (FFT), this computation can be performed quickly with O(nd log(d))
operations. In a very simplified scenario, a spectrum can be written as the sum of Gaussian-shaped
peaks plus some baseline noise in each mass channel. Since the convolution of two Gaussian densities
is again Gaussian, the original (local) structure of the spectra is essentially preserved in x˜i, whereas
the noise of xi is significantly reduced. Note that the deviation σ > 0 serves as a tuning parameter of
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the algorithm. A good choice of σ clearly depends on the nature of the data; usually it depends on the
noise level as well as on the (average) width of the peaks.
Finally, we would like to emphasize another interesting interpretation of the above smoothing
approach: The convolution in (9) can be written as a scalar product of xi with the shifted Gaussian
density Gσ(· − k) (note that Gσ is symmetric), that is, x˜i,k = 〈xi, Gσ(· − k)〉. Thus, the entries of x˜i
are actually the analysis coefficients of the Gaussian dictionary {Gσ(· − k) | k = 1, . . . , d}. The
perspective of analyzing data by a dictionary offers several opportunities for generalization. For
instance, one could also consider (redundant) dictionaries with more than one standard deviation or
more sophisticated functions than Gσ.
Step 3: Standardizing the Data
The 1-bit optimization of (7) does not incorporate a bias term. Hence, it is necessary to center the
data first. For this, we compute the mean spectrum12
x¯ := 1n
n∑
i=1
xi ∈ Rd,
i.e., x¯k contains the average of the k-th entry of all spectra. The spectra are further scaled by dividing
the non-constant features by their standard deviation
σj :=
√√√√ 1
n
n∑
i=1
(xi,j − x¯j)2, j = 1, . . . , d.
The standardized spectra xˇi = (xˇi,1, . . . , xˇi,d) ∈ Rd are then obtained by
xˇi,j :=
xi,j − x¯j
σj
, i = 1, . . . , n, j = 1, . . . , d.
In this way, all feature variables are centered and have an empirical standard deviation equal to 1, so
that they get equally weighted in the selection process.
Step 4: Sparse Feature Selection
We are now ready to perform the actual feature extraction step, using the 1-bit recovery method
presented in Subsection 2.2:
Algorithm 2 (1-Bit Compressed Sensing).
Input: Samples {(xi, yi)}i=1,...,n, sparsity parameter λ > 0, threshold  > 0
Output: Estimated feature vector ωˆ = (ωˆ1, . . . , ωˆd) ∈ Rd
Compute:
1: ωˆ′ = arg max
ω∈Rd
n∑
i=1
yi〈xi, ω〉 subject to ‖ω‖1 ≤
√
λ and ‖ω‖2 ≤ 1. (10)
2: ωˆk =
{
ωˆ′k, if |ωˆ′k| > ,
0, otherwise,
k = 1, . . . , d. (11)
The second part (in (11)) is a simple hard thresholding that tries to eliminate computational
inaccuracies by setting almost zero entries of ωˆ′ to 0 ( is usually very small, e.g., ∼ 10−3).
12 Actually, we use the smoothed data vectors x˜i from Step 2 as input for this computation. But in order to keep the
notation simple, we still write xi. This convention holds also for all forthcoming steps.
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The actual feature selection takes place in (10). Recalling the observation model from (8), we
conclude that the i-th sample is correctly classified by a vector ω if and only if yi〈xi, ω〉 > 0. Hence,
the objective functional of (10) will be particularly large if sufficiently many samples are correctly
classified by ω. However, a consistent prediction of all measurements (i.e., yi = sign(〈xi, ω〉) for all
i = 1, . . . , n) is not strictly enforced, and therefore, our strategy enjoys a certain robustness against
(random) perturbation of the model (8). This could occur in practice, for example, when a training
sample was wrongly classified from the very beginning. On the other hand, the constraint of (10)
guarantees that the maximizer will be “effectively” sparse (depending on the choice of the sparsity
parameter λ > 0). This intuition indicates that the estimator ωˆ will be indeed a sparse vector allowing
for an appropriate separation of the two classes.
Step 5: Detecting the Connected Components
One advantage of Algorithm 2 is that it does not make any assumptions on the structure of the data
vectors xi. Hence, it might be even suited for much more general types of data. However, its
“universality” comes with the drawback that the characteristic peak structure of MS data is not
captured at all. In fact, a spectrum does not consist of sharp spikes but rather wide-spread Gaussian
shaped peaks. Hence, if the algorithm finds a significant feature position, say at the maximum of some
peak, it usually tends to select also those features which are close to this position. Such a behavior is
not very surprising, because nearby features are highly correlated to the maximum of the peak, and
therefore, they may allow for a good separation as well.
Empirical results have shown that this process of selection “evolves” in a continuous fashion when
changing the sparsity level λ. As a consequence, the support of a feature vector ωˆ from Algorithm 2
typically consists of a few connected “intervals” (consecutive sequences of indices) which are centered
around the selected peaks (see also Fig. 3). The actual sparsity of ωˆ should be therefore measured by
means of its connected intervals and not by simply counting its non-zero entries.
For this reason, we may easily improve the sparsity of ωˆ by reducing every interval to its most
significant entry:13
Algorithm 3 (Sparsification of ωˆ).
Input: (Sparse) feature vector ωˆ = (ωˆ1, . . . , ωˆd) ∈ Rd
Output: Sparsified version ω˜ = (ω˜1, . . . , ω˜d) ∈ Rd
Compute:
1: Find the connected components A1, . . . , AN ⊂ supp(ωˆ) of ωˆ.
2: For every l = 1, . . . , N do the following:
Set all entries of ωˆ in Al to 0, except from arg maxk∈Al |ωˆk|.
3: The resulting vector is ω˜.
Step 6: Dimension Reduction
This final (optional) step does not involve any further computations but shows how to proceed with
our result ω˜. As mentioned before, the main purpose of SPA is not just to classify (unknown) samples,
but rather to reduce the data to its significant entries (dimensions). Indeed, we may use ω˜ for a
dimension reduction: Let x = (x1, . . . , xd) ∈ Rd be some (possibly unknown) data vector. Then, we
can project x onto the selected feature positions of supp(ω˜). More precisely, all entries that do not
13 Here supp(ωˆ) = {k | ωˆk 6= 0} denotes the support of ωˆ, i.e., the set of indices corresponding to its non-zero entries.
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Figure 3. The red stripe indicates the support of ωˆ. Relevant features usually occur as intervals and not as
isolated points.
belong to supp(ω˜) are set to 0:
xˆk :=
{
xk, k ∈ supp(ω˜),
0, otherwise,
k = 1, . . . , d. (12)
The resulting data vector xˆ = (xˆ1, . . . , xˆd) ∈ Rd is now trivially embedded into a low-dimensional
space of dimension # supp(ω˜).14 But it still contains the most important information which has been
found by the above algorithm. Note that we have not made any use of the actual values of ω˜ but
merely of its support.
By this projection, we may reduce the danger of overfitting. In particular, by working in a
low-dimensional space, a large tool set from machine learning is now available for classification and
clustering. But how to explicitly proceed with the data heavily depends on the specific application
and is therefore not part of SPA.
4 Experimental Results: Feature Selection from Simulated
Data-Sets
In this section, we assess our framework of SPA with regard to a typical situation in
mass-spectrometry analysis: We would like to extract discriminating features from MS data with
respect to two groups (e.g., healthy and diseased patients). A major difficulty is usually that only a
small number of measurements (observations) is available. Building on this, we ask for the following:
Given a simulated data-set for which the position and number of discriminating peaks are known (this
will be called ω0 below), how many samples are needed to identify these features with high accuracy?
We shall compare our results to the widely used state-of-the-art algorithms LIBLINEAR
(`1-regularized SVM) and the standard MATLAB implementation of Lasso.
4.1 Creating a Simulated Data-Set
We assume that our sample set {(xi, yi)}i=1,...,n ⊂ Rd × {−1,+1} follows a certain joint random
distribution (X,Y ), where each sample is independently drawn. In order to make the problem
tractable, let us make two model assumptions on X and Y . First, the mass spectra X are generated
as follows:
xi =
M∑
m=1
smi a
m + ni, i = 1, . . . , n,
14 In practice, one would simply reject all indices that are not contained in supp(ω˜).
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where smi ∈ Rd determines the (random) amplitude of the m-th peak, am ∈ Rd specifies its position
and shape, and ni ∈ R represents the low-amplitude baseline noise. We shall assume that the
amplitudes and the noise are Gaussian, that is, si := (s
1
i , ..., s
M
i ) ∼ N (0,Σ) with Σ ∈ RM×M positive
definite and ni ∼ N (0, σ2I) with σ > 0. Note that the generated data might have negative
components. This does not mimic the structure of real-world mass spectra which is always
non-negative. However, since centering is part of our preprocessing anyway (cf. Step 3 in
Subsection 3.2), the assumption of mean-zero amplitudes is quite natural. The (disease) labels Y are
then simply modeled as 1-bit observations (see also (8))
yi = sign(〈xi, ω0〉), i = 1, . . . , n, (13)
where ω0 ∈ Rd is the sparse ground-truth feature vector, which we intend to estimate. In the
following, each non-zero entry of ω0 is located at the center of a specific peak (see Fig. 4(d)–(f)), so
that supp(ω0) actually determines all biologically relevant peaks (molecular structures). Since Σ is
invertible (i.e., the features are linearly independent), this collection of peaks is an optimal fingerprint
in the sense that removing or adding any feature variable would decrease the prediction accuracy
(with respect to the “perfect” model of (13)).
In our experiments, we create data-sets x1, . . . , xn ∈ R8192, each one consisting of 200 equidistant
peaks (atoms am) shaped like Gaussian density function of width 10. The vector ω0 ∈ R8192 is chosen
to have five non-zero components, which means that only five prechosen peaks were used to generate
the labels y1, . . . , yn. Hereafter, we will refer to these as condition positive peaks. Fig. 4 shows three
different data instances magnifying only the first seven peaks, generated in the described way. In
order to verify our method, we will use two types of data-sets DS1 and DS2 which only differ in their
correlation matrix Σ. For DS1, Σ is chosen to be the identity matrix. This implies that the heights of
all of the 200 peaks are standard Gaussian random variables. For DS2, we have chosen three pairs of
negative peaks to be positively correlated and in addition, one condition positive peak was chosen to
be positively correlated with one of the negative peaks. Thus, there are a few entries of value 0.8 off
the main diagonal in Σ. To test the algorithm’s performance increasing amount of Gaussian noise
ni ∼ N (0, σ2) with σ = {0.1, 0.3} was added to DS1 and DS2. These corresponds to signal-to-noise
(SNR) ratio of 10, 3.33 repectively 15. The values of SNR are chosen to represent the behaviour of the
algorithm up to the levels of noise that are normally found in MS data.
4.2 Setup and Evaluation Criteria
Let us recall the essential question of our experiments: Can we recover the support of ω0, and if so,
how many samples do we need for that? For this purpose, we shall successively increase the number of
available samples in the (training) data-set and examine whether SPA (or Lasso, or `1-SVM) succeeds
in recovering supp(ω0). Since each of the considered algorithms involves a variable parameter, we have
decided to perform an adaptive tuning for each problem instance. In fact, the sparsity parameter was
chosen such that the resulting classifier ω˜ matches the sparsity level of ω0. But of course, this does not
automatically imply that the supports of ω˜ and ω0 completely coincide.
16 For each problem instance,
the smallest sparsity parameter which resulted in a classifier with five non-zero entries was chosen in
the following way: The initial value of the sparsity parameter for SPA and `1-SVM (Lasso) was set to
the value which corresponds to the classifier with less than (more than) five non-zero values17. For
SPA and `1-SVM (Lasso), the sparsity parameter was increased for a preset step size until the
outcome had five or more (five or fewer) non-zero entries. If the previous step provided a sparse
classifier with strictly more than (strictly less than) five non-zero entries, the bisection method was
used on the interval between the two last sparsity parameter values. The bisection method was used
until the optimal sparsity parameter was found or the difference between the two consecutive
parameters became smaller than a preset tolerance.
15 Signal-to-noise ratio was calculated as SNR = power of signal
power of noise
. 16 Due to the redundancy of the peak-associated
feature variables (cf. Step 5 in Subsection 3.2), an estimated feature vector is considered to be equal to the ground-truth
vector with some tolerance, which particularly depends on the width of the peaks. 17 This difference arises from the
implementation of Lasso.
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(a) (b) (c)
(d) (e) (f)
Figure 4. Illustration of the generated data instances. (a)–(c): First seven equidistant Gaussian peaks that
are located in fixed positions in each of the three data instances; (d)–(f): Visualization of the data instances
from (a)–(c) with additive noise with standard deviation σ = 0.1, where the positions of the five condition
positive peaks are highlighted by black dots. The blue and red colors indicate the different classes which are
determined by the observation process of (13).
We will use a measure based on sensitivity. Sensitivity, defined as18
sens := TPTP+FN
is an appropriate measure for our objectives because it represents an algorithm’s ability to detect
the relevant features. Note that ideally, the number of condition positives (TP + FN) is equal to
predicted condition positives (TP + FP ). In such a situation, the precision, given by
p := TP/(TP + FP ) is equal to the sensitivity. However, in the presence of noise it is possible that
the final selection encompasses several features which are associated with a single peak. This could
lead to a precision value equal to 1 if all of the selected values are declared as true positives, though
some other true features remain undetected. Since for us, it is equally important to penalize both false
positives and false negatives, we have chosen the sensitivity to be the main point of reference. A
measure of similar importance is the specificity, which is defined by
spec := TNFP+TN .
Finally, due to the possibly imbalanced number of relevant features, we shall also take into account
the so-called balanced accuracy
bacc := sens+ spec2 .
4.3 Results
Data-sets of sample sizes between 50 and 350 were generated as described above and each of the
methods was performed for standardized input data. Note that the hard thresholding step described
in (11) was also applied to the classifiers obtained from Lasso or `1-SVM. Otherwise, any
computational inaccuracy would completely destroy the sparsity structure of the results.
18 TP - true positives, i.e. correctly identified peaks
FP - false positives, i.e. incorrectly identified peaks
TN - true negatives, i.e. correctly rejected peaks
FN - false negatives, i.e. incorrectly rejected peaks
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Figure 5. Comparison of numerical results for SPA (= 1-bit CS), Lasso, and `1-SVM on the data-set DS1
with SNR = 10, and 3.33, showed in the respective row. Note that the data consist of 5 condition positive and
195 condition negative peaks which are equidistantly located in the spectra.
For the sake of statistical stability, each experiment was repeated 10-times. The averaged results
are presented in the Fig. 5. We can see that SPA (= 1-bit CS) performs better than the `1-SVM or
Lasso with regard to the capability of recognizing the true positive features (sensitivity in Fig. 5). In
our setting, if one method fails to select 5 condition positive peaks because one of them was selected
twice, and the other method selects exactly the same 4 peaks and one false positive in addition, the
specificity penalizes only the latter one. But effectively, both cases are suboptimal, since only the 5
positive peaks together can predict the class correctly. This effect is reflected by a smaller value of
specificity of the 1-bit approach comparing to the specificity of other two methods for data-sets with
less than 300 spectra (column 2 in Fig. 5). However, this also implies that SPA performs sligtly worse
in rejecting true negatives than the other two approaches. The average results for balanced accuracy
are visualized in the third column of Fig. 5. We observe that SPA outperforms the other two methods
and even achieves 100% accuracy with relatively few observations. With further decreasing SNR the
performance of the three algorithms becomes more similar. Fig. 6 shows the numerical outcomes for
the data-set DS2. The non-trivial correlation structure of DS2 eventually leads to a slight drop of
sensitivity and accuracy for SPA (compared to DS1), whereas the performance of the other two
methods essentially remains unaffected. As before with further decreasing SNR the performance of the
three algorithms becomes more similar in terms of sensitivity and balanced accuracy.
5 Experimental Results: Analyzing Real-World
MALDI-TOF MS Data
In this section, we present results of SPA, Lasso, and `1-SVM for analyzing real-world
mass-spectrometry data and compare them to the MALDIquant proteomics analysis workflow [37].
All data was acquired in our earlier studies [11,38]. It was approved by the local ethics committees
and fulfils the requirements of the Helsinki declaration. All subjects gave informed consent to
participate in the study. We will demonstrate the performance of our method on two data-sets:
• Spiked Data: The spiked data-set is a labelled ground-truth data-set containing control (e.g.
healthy) and case (e.g. diseased) mass spectra where the true labels are known. It is created
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Figure 6. Comparison of numerical results for SPA (= 1-bit CS), Lasso, and `1-SVM on the data-set DS2
with SNR = 10 and 3.33 showed in the respective row.
from human blood samples19 which were either unchanged (control group) or in which a
protein-mix has been mixed (spiked) into (case group). In order to simulate different strength of
an effect caused e.g. by a disease, we further sub-divided the case group into five sub-groups
where the amount of spiked-in proteins is increasing. The five volumes in the case sub-groups
were spiked with the following concentrations of the protein mix20: 0.075pMol/L, 3.03pMol/L,
0.30nMol/L, 0.76nMol/L and 121.21nMol/L. This mix contains the hormones Angiotensin,
ACTH, clip 18-39, Substance P and the cell protein Ubiquitin. The peptide mix was added
before sample pre-treatment and 64 spectra were measured due to 4-fold spotting (technical
replicates). Mass spectra were acquired using the protocol described in the supplementary
material (S1). Each volume corresponds to a data-set. What differentiates the data-sets are the
amplitudes of the 6 spikes resulting from the added substances. The signal-to-noise ratio of the
spiked-in peaks is shown in the Fig. 721.
• Pancreas Cancer Data (P. CA): A total of 120 patients with pancreatic cancer and controls were
recruited for this study [11]. For the discovery study sera were obtained from two different
clinical centres (University Hospital Leipzig (UHL, set L) and Heidelberg (UHH, set H)) as
described in the supplementary material (S1). Note that each acquired spectrum has been
assigned a class-label, i.e., healthy or diseased. So, the health status of the training samples is
known in advance (supervised learning).
Baseline removal was performed on the raw MS data using TopHat filtering ( [39]). In particular,
no additional calibration or noise reduction steps have been applied. More information on the data
and sample preparation can be found in the supplementary material (S1).
The missing-data problem
When dealing with data coming from measurements of, say, a Mass Spectrometer instrument, the so
called missing-data problem usually occurs. This means that the instrument failed to give
19 Blood serum of 16 apparently healthy individuals from a clinical study ( [38]) was used. 20 Protein calibration
standard mix Part No.: 206355 & 206196) from Bruker Daltronics (Leipzig, Germany) 21 The power of noise for each
of the 5 analyzed data-sets is estimated as an average of intensity of noise of the observations using median absolute
deviation.
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Figure 7. The height of true signals (6 spiked in peaks) comparing to the height of noise and height of the
corresponding values in the pure data-set. Signal-to-noise ratio, which was calculated as the ratio of median of
spiked-in signals and the estimated level of noise is shown above the corresponding peaks.
measurements for some of the measured masses, usually due to the stochastic nature of the process
happening inside the device. Due to the smoothing step in our algorithm and the arguments of e.g.
Rubin et al. ( [40]) this problem can be mainly ignored in our case for identifying the relevant features.
However, this does not necessarily hold for the classification step, i.e. applying the identified sparse
classifier to an unknown data-set. In this scenario, where data is missing in an unknown sample, there
are basically two options: (1) applying a method for inferring the missing data or (2) stopping the
classification and return an error message to the user. In this work we decided to follow the latter
approach, since inferring missing data is not in the scope of this paper22 but is an unarguable crucial
point in any data analysis pipeline and should depend on the actual use-case.
Accuracy vs. Number of Features
We performed these experiments with respect to the same evaluation categories as in the case of
simulated data. Note that the normalization and standardization as described in Section 3.2 were
applied as preprocessing steps in each of the methods. Similarly, a hard thresholding as described in
(11) was applied to all classifiers estimated by the examined algorithms.
For the each of the algorithms, we are testing the performance of the obtained classifiers learned on
the pure data-set which corresponds to the condition negative class and one spiked data-set at a time
corresponding to the condition positive class.
The results of the classifier with 6 non-zeros on the spiked data-set are shown in Table 2. The
main question in these experiments is how successful each of the algorithms is in detecting the 6 peaks
that were initially spiked (see the data-set description above). We can see that the values of sensitivity
for SPA are at least as high as those of the other methods, which implies that the approach of 1-bit
CS is very competitive in this situation and mostly achieves the best detection rate. However, the
relatively poor performance of all the algorithms on the spiked data-set can be explained by the
nature of the data. Since the peptide mix was added to the blood samples before acquiring the mass
spectra, the spiked peaks are not always present in all the resulting mass spectra in the positions
where we expect to find them. There exist data-sets for which all the mass spectra failed to exhibit
22 The interested reader might find a good starting point about this topic in these two reviews [41,42]
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certain spiked peaks at their expected locations as can be seen in the Fig. 7. Thus, we cannot expect
any of the algorithms to find these missing peaks. Nonetheless, there is still a chance to build a
reliable fingerprint out of the remaining spikes while there is no chance to detect the missing spikes
because the data-set is not rich enough to represent it. On the other hand, this spiked data-set
combines the advantages of both simulated and clinical data, since the positions of the desired
biomarkers are known in advance while their representative behavior in the spectra is quite realistic.
Figure 8. Accuracies of sparse classifiers from SPA, Lasso, and `1-SVM on the real pancreatic cancer
data-sets. While Lasso and `1-SVM achieve better classification accuracy with increasing number of features,
SPA is particularly well suited for the “very-sparse regime” where only few features (< 20) are used for
classification.
In contrast to that in the case of pancreas cancer data-sets, we do not know the true-positive
feature positions. Consequently, we can only rely on the classification performance of the obtained
sparse classifiers by each of the algorithms. To evaluate the reliability of our results, for each of the
methods, we have employed the cross-validation scheme as described in the Algorithm 4 with the
number of folds K set to 5. In order to ensure statistical stability, each experiment was repeated
10-times. Fig.8 shows the average results over 10 repetitions.
Algorithm 4 (Cross-Validation of Classification Performance).
Input: Raw data (x1, y1), ..., (xn, yn) ∈ Rd × {−1,+1}; Number of CV-folds K;
Output: Classification accuracy Acc ∈ [0, 1]; Average sparsity #F (number of selected features)
1: Split the sample set {1, ..., n} randomly into K disjoint folds P1, ..., PK of (almost) equal
size.
For each fold k ∈ 1, ...,K perform the following steps 2-4:
2: Compute the feature vector ωk employing the desired method on the samples of⋃
k′∈{1,...,K}\{k} Pk′
3: Dimension reduction as described in Sec. 3.2 (step 6). Project all spectra onto supp(ωk)
and put #F k := ||ωk||0.
4: Classification of Pk: Use the projected samples of
⋃
k′∈{1,...,K}\{k′} Pk′ to predict the labels
of the spectra Pk by an ordinary SVM
23. Denote the prediction accuracy by Acck.
5: Compute the average accuracy Acc := 1K
∑K
k=1Acc
k and average sparsity #F :=
1
K
∑K
k=1 #F
k.
In order to ensure statistical stability, each experiment was repeated 10-times. Fig. 8 shows the
results. Note that our results show that accurate predictions are already possible with a very few
23 Here, the standard MATLAB implementation of SVM was used.
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features, so that the assumption of small disease fingerprint seems to hold for this data-set.
Furthermore, it can be seen that SPA is especially well suited for situations where a sparse classifier
(containing only very few features) is preferred. This is appealing because fewer features enable an
easier interpretation of the actual components of a potential disease fingerprint. Moreover, follow-up
experiments that often involve an individual treatment of each component (e.g., potential biomarkers)
would become much less costly. Note that in the non-sparse region with more than 30 features
selected, it is not meaningful to relate the achieved accuracy to the quality of the learned feature
vector due to the small sample size. The considered algorithms assume the underlying fingerprint to
be sparse. This assumption usually does not fully hold in practice. Therefore, we cannot expect that a
learned feature vector achieves perfect classification. The classification accuracy should be therefore
considered as an indicator of how well our model assumption of the sparse fingerprint fits to the
unknown ground-truth. If we let the algorithms operate out of the region for which they have been
designed for, we may achieve indeed a higher accuracy, but this is probably a consequence of
overfitting. And even more importantly, the learned feature vector (model) is not reliable anymore.
Best Classifier
Apart from that, we are interested in the performance of the best sparse classifier (i.e. small number
of features) found by each of the algorithms (SPA, Lasso, `1-SVM). For all learned classifiers with 10
to 30 non-zero components, Table 3 presents those with the best classification accuracy. Furthermore,
we also considered a typical analysis pipeline (MALDIQuant) to see how the “purely-data-based”
approaches (SPA, Lasso, `1-SVM) compare to a model-based approach
24. In Table 3, it can be seen
that SPA provides the sparsest solutions while achieving competitive results with respect to sensitivity
and specificity at the same time. Lasso and `1-SVM select almost the same features and therefore
perform similarly. On the other hand, MALDIQuant selects the features based on a prior model-based
peak detection followed by a feature selection based on shrinkage diagonal discriminant analysis ( [43]).
But however, it still performs worst on the UHL data-set.
24 By “model-based” we mean that specific model assumptions on the data are made and exploited, such as noise-structure
for denoising or Gaussian-shaped structures for peak detection.
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SPA Lasso `1-SVM
Concentration TP[a] Sens[b] Spec[c] B. Acc[d] TP Sens Spec B. Acc TP Sens Spec B. Acc
0.075pMol/L 2 0.333 1.000 0.667 1 0.167 1.000 0.583 1 0.167 1.000 0.583
3.03pMol/L 4 0.667 1.000 0.833 2 0.333 1.000 0.667 1 0.167 1.000 0.583
0.30nMol/L 2 0.333 1.000 0.667 1 0.167 1.000 0.583 1 0.167 1.000 0.583
0.76nMol/L 2 0.333 1.000 0.667 2 0.333 1.000 0.667 2 0.333 1.000 0.667
121.21nMol/L 3 0.500 1.000 0.750 2 0.333 1.000 0.667 2 0.333 1.000 0.667
Table 2. This table shows the main results comparing the feature selection benchmarks of our approach with Lasso and `1-SVM on the spiked data-set.
Given results correspond to the average results over 10 repetitions of the classifier with 6 non-zero values.
[a] TP: Number of spiked peaks that are correctly detected; [b] Sens: Sensitivity in detecting spiked peaks (TP/(TP +FN)); [c] Spec: Specificity
in detecting spiked peaks (TN/(FP + TN)); [d] B. Acc: Balanced Accuracy ( sens.+spec.2 );
SPA Lasso `1-SVM Maldi-Quant
Dataset Feat.[e] Sens[f ] Spec[g] B. Acc[h] Feat. Sens Spec B. Acc Feat. Sens Spec B. Acc Feat. Sens Spec B. Acc
P. CA - UHL 20.48 0.975 0.949 0.962 29.94 0.969 0.939 0.954 27.72 0.964 0.947 0.955 21 0.888 0.888 0.888
P. CA - UHH 17.1 0.986 0.975 0.981 26.46 0.966 0.969 0.967 29.68 0.966 0.976 0.971 17 0.975 0.963 0.969
Table 3. This table shows the main results comparing the feature selection benchmarks of our approach with Lasso, `1-SVM, and Maldi-Quant. These are
averages over 10 repetitions of a 5-fold cross-validation. Note that these results have been calculated based on the highest accuracy criterion for all classifiers
with between 10 and 30 selected features. This particularly means that better accuracy values might be achieved for the individual methods if less sparse
feature vectors would be allowed. For more details see text.
[e] Feat.: Number of features; [f ] Sens: Sensitivity (TP/(TP +FN)); [g] Spec: Specificity (TN/(FP +TN)); [h] B. Acc: Balanced Accuracy ( sens.+spec.
2
);
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Medical Interpretation of Results
Pancreatic cancer is not only a common and increasingly frequent [44], but also still a fatal disease,
with a survival rate of 3-5% five years after diagnosis [45]. The conventional tumor marker,
Carbohydrate Antigen 19-9 (CA19-9), as a blood group antigen not present in a significant proportion
of the patients [46], shows insufficient diagnostic sensitivity and specificity (AUC 0.71), even in
combination with the second-line tumor marker Carcinoembryonic Antigen (CEA, combined AUC
0.75) [47]. The need for better markers for screening and differential diagnosis is evident, as panceratic
carcinoma would be principally curable if detected and identified very early in the course of the
disease. Along with the emerging “-omics”-technologies great hope was rised to find tumor-specific
peptides or metabolic alterations to increase sensitivity and specificity of early and differential
diagnostics, and several combinatory marker models could be identified by proteomics [11] and
metabolomics [48]. Pancreatic carcinoma is a complex disease - it affects the metabolism as a whole
(e.g. the so-called Warburg effect) [49], but also alters proteolytic activity [50]. Therefore, it might be
na¨ıve to expect a single marker capable to indicate presence, progression and exact type of the
malignancy at once [51] 9– it might even be overly reductionistic to attribute these capabilities to a
single model, even if it consists of several entities measured by different “- omics” technologies [46]. As
Raftery states “basing inferences on a single “best” model as if the single selected model were true
ignores model uncertainty, which can result in underestimating uncertainty about quantities of
interest” [52], and the larger the “-omics” data-sets grow, the larger is the ‘probability, that there is
not one “single best” predictive marker model, but instead several with comparable selectivity [51].
And it is very reasonable to assume that, even on the same data-set, different algorithms might favor
different models consisting of different feature sets and bring forth completely different results, when
only the best differentiating models are regarded. For an in-depth comparison of the validity of the
results of different algorithms, the underlying peak features should also be taken into account, and
similarities in the selected features corroborate the algorithms superimposed on them. In the case of
our study, we have the great advantage, that the same data-set was evaluated in three different
studies: the principal one by Fiedler et al. [11], a subsequent BinDA-algorithm-based manuscript by
Gibb and Strimmer published recently [53], and the present one. Fiedler et al. [11] identified one
discriminating peptide, Platelet Factor 4 (m/z 3884, identified in italics, double hits in bold) within
four discriminating peaks (m/z 3194, 3884, 4055, and 5959). The 30 most differential peaks in Gibb
et al. [53] were m/z 4495, 8868, 8989, 1855, 4468, 8937, 2023, 1866, 5864, 5946, 1780, 2093, 5906,
5960, 8131, 1207, 4236, 2953, 9181, 1021, 1466 , 4092, 4251, 5005, 8184, 1897, 3264, 2756, 6051, and
1264, with m/z 8937 identified as pancreatic progenitor cell differentiation and proliferation factor-like
protein. m/z 3884 could not be identified as discriminating marker (while it might play a role in
pancreatic carcinoma nonetheless [54]), whereas m/z 1466 can be attributed to a fragment of
fibrinopeptide A (DSGEGDFLAEGGGVR), as previously described in tumor samples [55]. In the
present study, the peaks m/z 1464 , 1546, 1944, 5904, 1619, 4209, and 2662 could be identified as
discriminating features. The slight mass shift of about 2 Da for m/z 1464 / 1466 and 5904 / 5906
is probably arising from different peak preprocessing procedures, peaks are wide enough to tolerate
this deviation. Further investigations and the application of further algorithms on the same data-set
are highly likely to yield a similar, partially overlapping set of features, each with a comparable
discriminating power (Fiedler et al. [56] AUC[3884/(CA19−9∗CEA)] 1.0; Gibb et al. [53] in a 5-feature
model: accuracy of 0.96, sensitivity of 0.96, specificity of 0.97, positive predictive value of 0.97 and
negative predictive value of 0.95; the present study accuracy[UHL] 0.96, sensitivity[UHL] 0.97,
specificity[UHL] 0.95 and accuracy[UHH] 0.98, sensitivity[UHH] 0.99, specificity[UHH] 0.97. This also
corresponds to a recently published comparable study investigating a glycoprotein marker panel (AUC
0.95) [57]. Biomarkers for clinical diagnostics comprise a wide field of applications (e.g.
population-wide screening, early diagnostics, characterization, treatment guidance, efficacy and
toxicity monitoring, prognosis, susceptibility estimation and many more) [46], each with special
requirements for sensitivity and specificity, that are only partially condensed in the AUC as an overall
selectivity measure [51]. Especially for screening purposes, sensitivity is extremely important [48], and
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clinically applied tests e.g. for newborn screening frequently surpass the 0.99 hallmark [56]. Compared
with the conventional, “not-for-screening” marker CA19-9, the SPA-based model shows considerable
improvement, however there is still a big gap to screening suitability, which in the next years might be
bridged by improved sensitivity of new instrumentation, refined algorithms (as the SPA), and
combination with other “markers” from the “big data” field, enabling a more holistic view – not only
of the disease, but also of the affected patient [46].
6 Conclusion
In this work, we introduced Sparse Proteomics Analysis (SPA), a new framework for the analysis of
proteomics data, generated by mass spectrometry measurements. The framework solves the problem
of selecting a minimum set of features from high-dimensional data in a situation where only relatively
few measurements are available. Our approach particularly allows for a bio-medical interpretation and
enables a classification of unknown samples. This is done by formulating and solving a regularized
optimization problem, using ideas from 1-bit compressed sensing combined with several generic pre-
and postprocessing steps. We have shown by several numerical experiments that SPA can indeed
compete with standard (and widely used) algorithms as well as with a specifically adapted method for
the analysis of proteomics data (MALDIQuant). In the “very-sparse” situation, it has even turned out
that SPA outperforms the other approaches with respect to prediction accuracy.
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Supporting Information
S1 - Mass Spectrometry Data Generation
Chemicals, Standards and Consumables
Gradient grade acetonitrile, ethanol, and HPLC-water were obtained from J.T. Baker (Phillipsburg,
NJ, USA); p.a. trifluoroacetic acid (TFA) and acetone were purchased from Sigma-Aldrich
(Taufkirchen, Germany). The peptide- and protein MALDI-TOF calibration standards I and
α-cyano-4-hydroxycinnamic acid (HCCA) were purchased from Bruker Daltonics (Bremen, Germany).
Automated magnetic bead preparations were performed using 96 well plates, TubePlates from Biozym
(Hessisch Oldendorf, Germany), polypropylene tubes (low profile) from Abgene (Surrey, UK), and
modular reservoir quarter modules from Beckman (Fullerton, USA). For sample storage 450 µL
CryoTubesTM were purchased from Sarstedt (Nmbrecht, Germany). Multifly needle sets and
polypropylene serum monovettes with clotting activators were also obtained from Sarstedt.
Peptidome Separation
All serum samples of the discovery set were processed at one time and analyzed simultaneously to
avoid procedure-dependent errors. The external validation set was prepared, processed and analyzed
separately. Peptidome separation of the samples was performed using the ClinPro Tools profiling
purification kits from Bruker Daltonics. Magnetic particles with defined surface functionalities
(magnetic beadimmobilized metal ion affinity chromatography (MB-IMAC Cu), magnetic
bead-hydrophobic interaction (MB-HIC C8) and weak cation exchange (MB-WCX)) were processed by
the ClinPro Tools liquid handling robot according to the manufacturers protocol (Bruker Daltonics).
Serum specimens were thawed on ice for 30 min and immediately processed according to our
standardized protocol for serum peptidomics [58].
Mass Spectrometry
A linear MALDI-TOF mass spectrometer (Autoflex I, Bruker Daltonics) was used for the peptidome
profiling. Daily mass calibration was performed using the standard calibration mixture of peptides
and proteins in a mass range of 1-10 kDa. Mass spectra were recorded and processed using
AutoXecute tool of the flexControl acquisition software (Ver. 2.0; Bruker Daltonics). The settings
were applied as follows: Ion source 1: 20 kV; ion source 2, 18.50 kV; lens, 9.00 kV; pulsed ion
extraction, 120 ns; nitrogen-pressure, 2500 mbar. Ionization was achieved by a nitrogen laser (λ=337
nm) operating at 50 Hz. For matrix suppression a high gating factor with signal suppression up to 500
Da was used. Mass spectra were detected in linear positive mode.
Baseline Removal
The baseline is an exponential like offset dependent on the m/z value (mass-to-charge; x-value). A
baseline correction is performed to remove this rather low-frequency noise from the spectrum. We use
a morphological TopHat filter to eliminate certain spatial structures within the signal, in our case the
baseline. Note that this technique does not produce negative intensity values.
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